The green light from the European Commission comes a few months after pan-FGFR inhibitor Balversa (erdafitinib) was cleared for the same indication in the US, with a different label than the drug ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable FGFR-altered urothelial carcinoma (UC) who have previously ...

The National Institute of Health and Care Excellence (Nice) has recommended erdafitinib, also known as Balversa and manufactured by Johnson & Johnson, for some adult patients in England.